Searched for
DIVI S LAB
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- FIIs bought 120 Indian stocks in Q4 amid Rs 1.3 lakh crore exodus. What's special about them?Despite a significant Rs 1.3 lakh cr exodus in Q4, Foreign Institutional Investors selectively increased stakes in 120 Indian stocks. These...
- Divi’s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?Divi's Laboratories reported a strong Q4FY25, with a 26% YoY increase in net profit to Rs 667 crore and a 12.26% rise in revenue to Rs 2,53...
- Divi’s Labs Q4 Results: Cons PAT slumps 64% YoY to Rs 321 crore; Rs 30/share dividend declaredOperating profit, calculated as earnings before interest, taxes, depreciation and amortization (EBITDA), plunged 56% YoY to Rs 488 crore in...
- Divi’s Labs Q4 Results: Profit surges 78% YoY to Rs 895 crore, beats estimatesThe Board of Directors of the company has recommended a dividend of Rs 30 per share for the financial year 2021-22, subject to approval of ...
- Divi’s Labs hits all-time high after robust Q2 resultsA recent entrant to the Nifty pack, Divi’s Labs is up 82 per cent year-to-date, and has almost doubled over the last one year.
- Divi’s Labs Q2 preview: Firm to maintain momentum, PAT to grow in double digitsDivi’s Labs has been one of the best performing pharma companies this year, as far as market returns are concerned.
- Buy Divi’s Lab with target price of Rs 1,375: Prakash GabaDivi’s Lab is a 'BUY' call with a target of Rs 1,375 and a stop loss of Rs 1,318.
- Buy Divi’s Lab with target price of Rs 1,375: Mitesh ThackerDivi’s Lab is a 'BUY' call with a target of Rs 1,375 and a stop loss of Rs 1,314.
- Divi’s Lab can climb to levels closer to 1160: Prakash GabaDivi’s Lab can climb to levels closer to 1160, stop below 1100 zones.
- Buy Divi’s Lab with target price of Rs 1060: Mitesh ThackerDivi’s Lab is a 'BUY' call with a target of Rs 1060 and a stop loss of Rs 994.
- Buy Divi’s Lab with target price of Rs 1005: Sandeep WagleBuy Divi’s Lab at a stop of Rs 978.
- Buy Divi’s Lab with target price of Rs 985: Mitesh ThackerBuy Divi’s Lab at a stop of Rs 969.
- Buy Divi’s Labs with a target of Rs 1,073: Deepak MohoniBuy Divi’s Labs with a stop loss of RS 1,018.
- Buy Divi’s Lab with a target price of Rs 1086: Mitesh Thacker" Divi’s Lab is a buy call with a target price of Rs 1086 and a stop loss of Rs 1048."
- Sell Divi’s Lab with target of 1120: Mitesh ThackerDivi’s Lab is a ‘Sell’ call with a target of Rs 1120 and a stop loss of Rs 1172.
- Buy Divi’s Lab with a target of Rs 1230: Sandeep Wagle"I am buying Divi’s Lab, stop loss 1175, target 1230. Divi’s Labs has not moved that much, there is more scope for upside move."
- Buy Divi’s Labs with a stop loss of Rs 1165: Deepak MohoniDivi’s Labs is a 'BUY' call with a target of Rs 1234 and a stop loss of Rs 1165
Load More
